Nov 27, 2014 - Individualized cancer chemotherapy (ICC) has been designed to meet the ... cancer pathology, biochemistry, pharmacology and clinical ...
Personalized Cancer Chemotherapy_ 9780081003466
Spine TBC
WOODHEAD PUBLISHING SERIES IN BIOMEDICINE
• explores the central components of cancer treatment • investigates new developments in cancer treatment • discusses the many strategies of individualized cancer chemotherapy Da Yong Lu is an Associate Professor at Shanghai University, P.R China studying cancer pathology, biochemistry, pharmacology and clinical therapeutics, especially on the pharmacological studies of new Chinese anticancer agent probimane and MST-16, antimetastatic targets of fibrinogen and sialic acids, individualized cancer chemotherapy (ICC) and some articles in avian flu, AIDS and neural science. His research interests are focused on the basic studies of cancer biology, pathology, treatment, origins of life and other field of science disciplines. He is as a member of several reputed international journals and has also published more than 50 scientific articles in international journals.
An imprint of Elsevier • store.elsevier.com
Personalized Cancer Chemotherapy_AW1.indd All Pages
WOODHEAD PUBLISHING SERIES IN BIOMEDICINE
Personalized Cancer Chemotherapy An Effective Way of Enhancing Outcomes in Clinics Da Yong Lu
Lu
ISBN 978-0-08-100346-6
Personalized Cancer Chemotherapy
Key features include:
720 An Effective Way of Enhancing Outcomes in Clinics
Individualized cancer chemotherapy (ICC) has been designed to meet the requirement of selecting anticancer drugs in clinics and attracting increasing attentions in medical circle and will show more beneficial outcome in the future if we stick on these researches. Personalized Cancer Chemotherapy addresses and reviews this issue by discussing many existing specific strategies of ICC, including drug sensitivity testing, cancer biomarker detections, cancer biomarker-oriented therapy, anticancer drug pharmacogenetics, cancer metastasis therapy, anticancer drug combinations, assistant therapy, mathematics, and computational analysis of cancer malignancy and drug responses, cost effective and finally studies of relationship between different ICC strategies. The relationship between drug response and these techniques or methods is in-depth analyzed, discussed and highlight. Many longstanding key debates and future trends are also intensively discussed, highlighted and debuted with new twists.
